Gerard Zurawski
50Patents
14h-index
33Co-inventors
84Inventor score
Filing activity: Sep 4, 1986 → Jun 6, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5596072A | Method of refolding human IL-13 | Emerging Cross-Sectional Technologies | 51 | Expired |
| US5696234A | Muteins of mammalian cytokine interleukin-13 | Human Necessities | 42 | Expired |
| US7786267B2 | Multivariable antigens complexed with targeting humanized monoclonal antibody | Chemistry; Metallurgy | 42 | Active |
| US8518410B2 | Fusion protein with HIV antigen | Emerging Cross-Sectional Technologies | 40 | Active |
| US9102734B2 | Fusion proteins comprising antibody and HPV E6 and E7 antigens | Emerging Cross-Sectional Technologies | 39 | Active |
| US8961991B2 | Anti-CD40 targeted fusion proteins | Emerging Cross-Sectional Technologies | 38 | Active |
| US8449888B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 34 | Active |
| US8236934B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 32 | Active |
| US5001230A | T cell activation markers | Chemistry; Metallurgy | 31 | Expired |
| US8728481B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 30 | Active |
| US9102730B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 25 | Active |
| US8586052B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 25 | Active |
| US9416186B2 | Antigen presenting cell targeted anti-viral vaccines | Emerging Cross-Sectional Technologies | 25 | Active |
| US9234040B2 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | Chemistry; Metallurgy | 25 | Active |
| US9109011B2 | Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef | Chemistry; Metallurgy | 13 | Active |
| US6479638B1 | Antibodies that specifically bind DNAX leukocyte associated immunoglobulin-like receptor | Chemistry; Metallurgy | 10 | Expired |
| US5017692A | Truncated human interleukin-a alpha | Chemistry; Metallurgy | 10 | Expired |
| US8481314B2 | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1) | Emerging Cross-Sectional Technologies | 9 | Active |
| US9339556B2 | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1) | Emerging Cross-Sectional Technologies | 9 | Active |
| US6140098A | Nucleic acids encoding mammalian proteinases; related reagents | Emerging Cross-Sectional Technologies | 8 | Expired |
| US9562104B2 | Anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 5 | Active |
| US9315580B2 | Vaccines directed to langerhans cells | Chemistry; Metallurgy | 5 | Active |
| US7005501B2 | Purified mammalian cytokines; related reagents and methods | Human Necessities | 4 | Expired |
| US7655761B2 | IL-17-like cytokine binding compounds and antibodies | Human Necessities | 3 | Active |
| US7999078B2 | Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor | Emerging Cross-Sectional Technologies | 2 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.